Molecular Partners has published the invitation to its Annual General Meeting 2018.
Molecular Partners publishes its audited Financial Results for 2017 and the company’s 2017 Annual Report.
Molecular Partners presents at the Cowen and Company 38th Annual Healthcare Conference in Boston.
Molecular Partners’ collaboration partner Allergan has exercised the third option to develop and commercialize DARPin® product candidates from its 2012 discovery alliance agreement with Molecular Partners.
Molecular Partners reports its unaudited financial results for 2017, a year marked by promising clinical data in oncology as well as the successful, early completion of patient recruitment for phase 3 studies of abicipar.
Molecular Partners announced initial safety and efficacy data from its ongoing phase 2 study of MP0250 in multiple myeloma (MM).
Molecular Partners presents at the 36th Annual J.P. Morgan Healthcare Conference.
Molecular Partners announced that Allergan has exercised two options to develop and commercialize DARPin® product candidates from its 2012 discovery alliance agreement with Molecular Partners.
Molecular Partners holds its R&D update in New York, entitled “The DARPin® Difference – Offering Patients a New Dimension of Protein Therapeutics”, which features a series of presentations highlighting the scientific rationale and the potential clinical impact of the DARPin® approach, as well as the company’s continued forward integration and evolution towards becoming a fully integrated biopharmaceutical company.
At the EGM the shareholders of Molecular Partners approved the election of William (Bill) Burns, former CEO of Roche Pharmaceuticals, and Patrick Amstutz, CEO of Molecular Partners, as new members of the Board of Directors with large majorities.